Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma

Traditionally, overall survival (os) has been considered the “gold standard” for evaluating new systemic oncologic therapies, because death is easy to define, is easily compared across disease sites, and is not subject to investigator bias. However, as the available options for continuing therapy in...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Hotte, S.J., Bjarnason, G.A., Heng, D.Y.C., Jewett, M.A.S., Kapoor, A., Kollmannsberger, C., Maroun, J., Mayhew, L.A., North, S., Reaume, M.N., Ruether, J.D., Soulieres, D., Venner, P.M., Winquist, E.W., Wood, L., Yong, J.H.E., Saad, F.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Multimed Inc. 2011
Konular:
Medical Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3176905/
https://ncbi.nlm.nih.gov/pubmed/21969807
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller